Split-dose administration of thiopurine drugs: A novel and effective strategy for managing preferential 6-MMP metabolism

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 5, 2012, Pages 449-458

  Shih, D Q ^a   Nguyen, M ^a   Zheng, L ^a   Ibanez, P ^b   Mei, L ^a   Kwan, L Y ^a   Bradford, K ^a   Ting, C ^c   Targan, S R ^a   Vasiliauskas, E A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c SGV Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; DRUG METABOLITE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHYLMERCAPTOPURINE; PURINE DERIVATIVE; TIOGUANINE; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; COLITIS; COLON RESECTION; CROHN DISEASE; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERITIS; ERYTHROCYTE LEVEL; FEMALE; FLU LIKE SYNDROME; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; ULCERATIVE COLITIS; UNITED STATES;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AZATHIOPRINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864680763     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05206.x     Document Type: Review

References (35)

1. Tiede I, Fritz G, Strand S, et al,. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 1133-45.
2. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS,. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-7.
3. Chebli LA, Chaves LD, Pimentel FF, et al,. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis 2010; 16: 613-9.
4. Prefontaine E, Macdonald JK, Sutherland LR,. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2009; 4: CD000545.
5. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M,. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009; 1: CD000067.
6. Bradford K, Shih DQ,. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol 2011; 17: 4166-73.
7. Hindorf U, Lindqvist M, Peterson C, et al,. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006; 55: 1423-31.
8. Dubinsky MC, Lamothe S, Yang HY, et al,. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.
9. Dubinsky MC, Yang H, Hassard PV, et al,. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-15.
10. Sparrow MP, Hande SA, Friedman S, et al,. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005; 22: 441-6.
11. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB,. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007; 5: 209-14.
12. Mardini HE, Arnold GL,. Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting. J Clin Gastroenterol 2003; 36: 390-5.
13. Cuffari C, Hunt S, Bayless T,. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 642-6.
14. Gearry RB, Barclay ML,. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005; 20: 1149-57.
15. Lennard L, Singleton HJ,. High-performance liquid chromatographic assay of human red blood cell thiopurine methyltransferase activity. J Chromatogr B Biomed Appl 1994; 661: 25-33.
16. Weinshilboum RM, Sladek SL,. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-62.
17. Bloomfeld RS, Onken JE,. Mercaptopurine metabolite results in clinical gastroenterology practice. Aliment Pharmacol Ther 2003; 17: 69-73.
18. Dubinsky MC, Hassard PV, Seidman EG, et al,. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001; 7: 181-9.
19. Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA,. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003; 98: 1058-63.
20. Dubinsky MC, Vasiliauskas EA, Singh H, et al,. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003; 125: 298-303.
21. Ansari A, Patel N, Sanderson J, O'Donohue J, Duley JA, Florin TH,. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 640-7.
22. Rahhal RM, Bishop WP,. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1678-82.
23. Witte TN, Ginsberg AL,. Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature. Can J Gastroenterol 2008; 22: 181-5.
24. Zazgornik J, Kopsa H, Schmidt P, Pils P, Kuschan K, Deutsch E,. Increased danger of bone marrow damage in simultaneous azathioprine-allopurinol therapy. Int J Clin Pharmacol Ther Toxicol 1981; 19: 96-7.
25. Govani SM, Higgins PD,. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. J Crohns Colitis 2010; 4: 444-9.
26. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA,. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2004; 13: 563-7.
27. Bouhnik Y, Lemann M, Mary JY, et al,. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215-9.
28. Beigel F, Jurgens M, Tillack C, et al,. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease. Nat Rev Gastroenterol Hepatol 2009; 6: 433-6.
29. Shale M, Kanfer E, Panaccione R, Ghosh S,. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008; 57: 1639-41.
30. Ochenrider MG, Patterson DJ, Aboulafia DM,. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin Lymphoma Myeloma Leuk 2010; 10: 144-8.
31. Kotlyar DS, Osterman MT, Diamond RH, et al,. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 36-41.
32. Keane J, Gershon S, Wise RP, et al,. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
33. Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X,. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 15-36.
34. Armstrong L, Sharif JA, Galloway P, McGrogan P, Bishop J, Russell RK,. Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine. Aliment Pharmacol Ther 2011; 34: 1106-14.
35. de Boer NK, Wong DR, Jharap B, et al,. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 2007; 102: 2747-53.